PRPH - Mergers and acquisitions

GARDEN CITY, NY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. "ProPhase" (NASDAQ:PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it has entered into an asset purchase agreement to acquire from Stella Diagnostics, Inc. ("Stella") world-wide exclusive rights to Stella's BE-Smart Esophageal Pre-Cancer diagnostic screening test and related intellectual property assets for approximately $4.5 million dollars, comprised of approximately $3.5 million in cash and $1 million in ProPhase common stock. Under the terms of the agreement, an additional $2 million of Company common stock may be issued to Stella in the future upon the achiev

ROCHESTER, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE:DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced Global BioLife, Inc. ("Global BioLife"), a subsidiary of the Company's wholly owned subsidiary Impact BioMedical, Inc. ("Impact BioMedical"), executed a license agreement with ProPhase BioPharma, Inc. ("PBIO"), a subsidiary of ProPhase Labs, Inc. (NASDAQ:PRPH), a rapidly growing and diversified diagnostics, genomics and biotech company, for Global BioLife's Linebacker por

Nebula Founder and Renowned Harvard Scientist, George Church, Ph.D., to Spearhead ProPhase Labs New Scientific Advisory Board GARDEN CITY, NY, Aug. 11, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a diversified medical science and technology company, today announces the acquisition of Nebula Genomics, a privately-owned personal genomics company. The Company's recently formed subsidiary, ProPhase Precision Medicine, Inc., completed the acquisition for approximately $14.6 million in a combination of ProPhase Labs common stock and cash. The Company intends to integrate Nebula's whole genome sequencing services with the robust clinical diagnostic t

 New Reporting App Simplifies Documentation of User Vaccination and Covid Testing Statue – Easily Enables Clear Access to Air/Rail/Bus Travel, Concert & Sporting Events GARDEN CITY, NY, March 30, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today that it has acquired the “VaccTrack” suite of digital solutions that can provide secure and reliable certification of a user’s vaccination and Covid testing results. A digital vaccination certificate, or “passport” is based on a mobile app that confirms that a user has been vaccinated against Covid-19, or, if the user has been tested for Covid-19, can confir